MBIO MUSTANG BIO, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1680048 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-51.1%
TTM EPS YoY92.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-43.1%
ROA-20.7%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets55.1%
Debt / equity0.00x
Current ratio—
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.29x
Accruals ratio6.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | — | — | — | — | — | — | — | -$664,000 |
| SG&A expense | $850,000 | $946,000 | $880,000 | $987,000 | $957,000 | $787,000 | $1.22M | -$223,000 |
| Operating income | -$1.06M | -$1.17M | -$1.06M | -$670,000 | -$624,000 | -$885,000 | -$253,000 | -$1.02M |
| Interest expense | — | — | — | — | — | — | — | $1,000 |
| Net income | -$964,000 | -$1.07M | -$955,000 | -$538,000 | -$468,000 | -$762,000 | -$153,000 | -$952,000 |
| EBITDA | -$1.06M | -$1.17M | -$1.06M | -$670,000 | -$624,000 | -$885,000 | -$219,000 | -$966,000 |
| EPS (basic) | -0.14 | -0.16 | -0.14 | — | -0.07 | -0.19 | -0.05 | — |
| EPS (diluted) | -0.14 | -0.16 | -0.14 | — | -0.07 | -0.19 | -0.05 | — |
| Weighted avg. shares (diluted) | 6.74M | 6.73M | 6.73M | — | 6.24M | 4.02M | 2.86M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $14.28M | $15.15M | $16.26M | $17.27M | $18.98M | $12.66M | $14.23M | $6.84M |
| Current assets | — | — | — | $17.59M | $19.36M | $13.05M | $14.91M | $8.61M |
| PP&E, net | — | — | — | $0 | $0 | $0 | $0 | $371,000 |
| Total assets | $14.68M | $15.61M | $16.58M | $17.59M | $19.36M | $13.05M | $14.91M | $9.31M |
| Current liabilities | $7.95M | $7.92M | $7.84M | $7.91M | $9.44M | $10.00M | $11.15M | $12.61M |
| Total liabilities | $8.10M | $8.07M | $7.99M | $8.06M | $9.59M | $10.15M | $11.30M | $13.18M |
| Shareholders' equity | $6.59M | $7.54M | $8.60M | $9.53M | $9.77M | $2.89M | $3.61M | -$3.87M |
| Cash flow statement | ||||||||
| Operating cash flow | -$876,000 | -$967,000 | -$1.01M | -$1.72M | -$818,000 | -$1.34M | -$1.39M | -$2.00M |
| Capital expenditure | — | — | — | — | — | — | — | $0 |
| Free cash flow | — | — | — | — | — | — | — | -$2.00M |
| Investing cash flow | $0 | $0 | $0 | $0 | $0 | $0 | $1.17M | $0 |
| Financing cash flow | $2,000 | -$141,000 | $0 | $0 | $7.14M | -$235,000 | $7.62M | $4.94M |
| Depreciation & amortization | $0 | $0 | $0 | $0 | $0 | $0 | $34,000 | $51,000 |
| Stock-based compensation | $2,000 | $21,000 | $22,000 | $23,000 | $23,000 | $45,000 | $38,000 | $50,000 |
Free plan shows the latest 8 periods; Pro shows all 46 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.